(Q37732337)

22 August 2017

1 reference

title

P-glycoprotein related drug interactions: clinical importance and a consideration of disease states (English)

1 reference

22 August 2017

1 reference

Caroline A Lee

1

1 reference

22 August 2017

Jack A Cook

series ordinal

2

1 reference

22 August 2017

Eric L Reyner

series ordinal

3

1 reference

22 August 2017

Dennis A Smith

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Drug Metabolism & Toxicology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

603-619

1 reference

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Structure-activity relationship of P-glycoprotein substrates and modifiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

ABC efflux pump-based resistance to chemotherapy drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Variable modulation of opioid brain uptake by P-glycoprotein in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Modulation of P-glycoprotein Transport Activity in the Mouse Blood-Brain Barrier by Rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The role of transporters in drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The Role of ABC Transporters in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Prediction of broad spectrum resistance of tumors towards anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Phase II evaluation of topotecan for pediatric central nervous system tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Multi-functional nanocarriers to overcome tumor drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The implications of P-glycoprotein in HIV: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Targeting anti-HIV drugs to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

beta-Amyloid efflux mediated by p-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

PhRMA white paper on ADME pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425251003610640

10.1517/17425251003610640

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference